Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9454.7200
Address
Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086
Description
Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.05
Trade Value (12mth)
AU$10,573.00
1 week
-11.76%
1 month
0%
YTD
57.89%
1 year
-25%
All time high
4.31
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
-$14m
Free Cash Flow Return
-202.20%
ROIC
-190.80%
Interest Coverage
-47.80
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
1092m
HALO Sector
Healthcare
Next Company Report Date
13-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 August 24 |
Appendix 4E and Annual Report to shareholders
×
Appendix 4E and Annual Report to shareholders |
30 August 24 |
Corporate Governance Statement 2024
×
Corporate Governance Statement 2024 |
30 August 24 |
Appendix 4G - Key to Corporate Governance Disclosures
×
Appendix 4G - Key to Corporate Governance Disclosures |
21 August 24 |
Notification of cessation of securities - SNT
×
Notification of cessation of securities - SNT |
20 August 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
16 August 24 |
Syntara appoints new CFO
×
Syntara appoints new CFO |
16 August 24 |
Notification regarding unquoted securities - SNT
×
Notification regarding unquoted securities - SNT |
16 August 24 |
Proposed Issue of Securities to Chief Executive Officer
×
Proposed Issue of Securities to Chief Executive Officer |
16 August 24 |
Notification of cessation of securities - SNT
×
Notification of cessation of securities - SNT |
16 August 24 |
Update - Notification regarding unquoted securities - SNT
×
Update - Notification regarding unquoted securities - SNT |
08 August 24 |
Change in substantial holding
×
Change in substantial holding |
08 August 24 |
German MDS group awarded $2.5m grant for phase 2 MDS trial
×
German MDS group awarded $2.5m grant for phase 2 MDS trial |
07 August 24 |
Change in substantial holding
×
Change in substantial holding |
06 August 24 |
Application for quotation of securities - SNT
×
Application for quotation of securities - SNT |
06 August 24 |
Section 708A(5)(e) notice
×
Section 708A(5)(e) notice |
31 July 24 |
Phase 2 blood cancer trial fully recruited
×
Phase 2 blood cancer trial fully recruited |
30 July 24 |
Placement
×
Placement |
30 July 24 |
Proposed issue of securities - SNT
×
Proposed issue of securities - SNT |
30 July 24 |
Equity Raising Presentation
×
Equity Raising Presentation |
30 July 24 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
30 July 24 |
Quarterly Activities Report
×
Quarterly Activities Report |
29 July 24 |
Trading Halt
×
Trading Halt |
01 July 24 |
Investor presentation
×
Investor presentation |
24 June 24 |
Change of Share Registry Management Services
×
Change of Share Registry Management Services |
12 June 24 |
SNT to present in MST Access Hidden Gems Webinar
×
SNT to present in MST Access Hidden Gems Webinar |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.